TabletsClinical Overview
Torasemide is a high-ceiling loop diuretic of the pyridine-sulfonylurea class. It inhibits the Na+/K+/2Cl- luminal carrier in the thick ascending limb of Henle's loop, producing potent natriuresis and diuresis. Unlike furosemide, torasemide features high, predictable oral bioavailability (around 80%), a longer duration of action, and antialdosterone properties that decrease myocardial collagen accumulation. Indicated for edema associated with congestive heart failure, chronic renal failure, and hepatic cirrhosis, and for essential hypertension.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with water, with or without meals. Morning dosing prevents sleep disruption from urination. Weigh yourself regularly.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Excessive urination, dizziness, headache, dehydration, hypokalemia, hypomagnesemia, muscle cramps. Rare/Severe: Boxed warning: Profound diuresis and electrolyte depletion; acute kidney injury, ototoxicity (tinnitus, hearing loss), and orthostatic collapse.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Potent loop diuretic; excessive amounts can cause profound diuresis with water and electrolyte depletion. Contraindicated in anuria and severe pre-coma hepatic encephalopathy. Regularly monitor serum electrolytes, BUN, and creatinine.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Spironolactone 50mg + Torasemide 20mg Tablets
Torasemide and Spironolactone is a balanced dual-action diuretic formulation. Torasemide is a high-potency pyridine-sulfonylurea loop diuretic that inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, while spironolactone is a competitive aldosterone receptor antagonist in the distal convoluted tubule and collecting duct. Spironolactone prevents loop diuretic-induced potassium wasting and secondary hyperaldosteronism, reducing cardiac fibrosis while promoting sustained natriuresis. Indicated for resistant edema associated with congestive heart failure, hepatic cirrhosis with ascites, and nephrotic syndrome.
Torasemide 10mg + Spironolactone 25mg Tablets
Torasemide (10mg) and Spironolactone (25mg) Tablets is a fixed-dose loop and potassium-sparing diuretic combination on the WHO Model List framework. Torasemide inhibits the Na+/K+/2Cl- symporter in the thick ascending limb of Henle's loop, producing potent natriuresis and diuresis. Spironolactone competitively antagonizes the mineralocorticoid aldosterone receptor in the distal convoluted tubule and collecting duct, promoting sodium and water excretion while conserving potassium and magnesium ions. Indicated for refractory edema and ascites associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome.
Torasemide 10mg + Amiloride 5mg Tablets
Torasemide (10mg) and Amiloride (5mg) Tablets is a fixed-dose loop and potassium-sparing diuretic combination. Torasemide blocks the Na+/K+/2Cl- cotransporter in the loop of Henle, while amiloride selectively blocks epithelial sodium channels (ENaC) in the late distal tubule and cortical collecting duct, preventing potassium loss driven by torasemide's high distal tubular sodium delivery. Indicated for refractory edema associated with congestive heart failure, nephrotic syndrome, and hepatic cirrhosis.